August 21, 2013 / 5:42 AM / 4 years ago

Belgian biotech firm Ablynx reports 12.9 million H1 revenue

BRUSSELS, Aug 21 (Reuters) - Belgian biotech company Ablynx NV reported on Wednesday revenues of 12.9 million euros and a net loss of 10.5 million at the end of the first half of 2013.

The company said it had a strong financial position, with 72 million euros in cash or cash equivalents.

Earlier in the year the firm raised 31.5 million euros in a private placement of new shares.

Reporting By Claire Davenport; editing by John O'Donnell

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below